Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

BACKGROUND: Chimeric antigen receptor T-cell therapy (CART) is effective for patients with refractory or relapsed lymphoma with prolongation of survival. We aimed to improve the prediction of Lugano criteria for overall survival (OS) at 30-day follow-up (FU1) by including the pre-infusion tumor grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkelmann, Michael, Blumenberg, Viktoria, Rejeski, Kai, Quell, Christina, Bücklein, Veit, Ingenerf, Maria, Unterrainer, Marcus, Schmidt, Christian, Dekorsy, Franziska J, Bartenstein, Peter, Ricke, Jens, von Bergwelt-Baildon, Michael, Subklewe, Marion, Kunz, Wolfgang G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603350/
https://www.ncbi.nlm.nih.gov/pubmed/37880181
http://dx.doi.org/10.1136/jitc-2022-006659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603350/
https://www.ncbi.nlm.nih.gov/pubmed/37880181
http://dx.doi.org/10.1136/jitc-2022-006659

Ejemplares similares